Royalty Pharma and Cytokinetics Announce Expanded Strategic Funding Collaboration Totaling Up to $575 Million to Support Commercial Launch of Aficamten and to Advance R&D Pipeline
Go back to Royalty Pharma and Cytokinetics Announce Expanded Strategic Funding Collaboration Totaling Up to $575 Million to Support Commercial Launch of Aficamten and to Advance R&D Pipeline| CYTOKINETICS (NASDAQ: CYTK) | Delayed: 68.78 -1.14 (1.63%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $69.92 | 52 Week High | $13.18 | |||
| Open | $70.18 | 52 Week Low | $6.00 | |||
| Day High | $70.18 | P/E | N/A | |||
| Day Low | $68.15 | EPS | $-1.24 | |||
| Volume | 4,872,971 | |||||
| REPROS THERAPEUTICS (NASDAQ: RPRX) | Delayed: 58.41 -0.52 (0.88%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $58.93 | 52 Week High | $3.48 | |||
| Open | $58.63 | 52 Week Low | $0.80 | |||
| Day High | $58.96 | P/E | N/A | |||
| Day Low | $57.97 | EPS | $-1.54 | |||
| Volume | 7,104,686 | |||||
